background
although
respiratori
syncyti
viru
rsv
lower
respiratori
tract
infect
lrti
earli
life
follow
later
airway
hyperreact
unclear
whether
causal
relationship
atop
diathesi
object
separ
effect
rsv
lrti
atop
diathesi
subsequ
recurr
wheez
examin
protect
effect
previou
palivizumab
administr
subsequ
recurr
wheez
infant
without
famili
histori
atopi
method
prospect
multicent
match
doubl
cohort
studi
conduct
center
europ
canada
rate
physiciandiagnos
recurr
wheez
prematur
infant
week
gestat
receiv
palivizumab
first
year
life
compar
gestat
agematch
control
result
rel
protect
effect
palivizumab
physiciandiagnos
recurr
wheez
age
year
famili
histori
asthma
odd
ratio
ci
n
palivizumabtr
untreat
famili
histori
atopi
food
allergi
odd
ratio
ci
n
palivizumabtr
untreat
contrast
effect
palivizumab
subsequ
recurr
wheez
children
famili
histori
atopi
food
allergi
compar
untreat
infant
atop
famili
conclus
respiratori
syncyti
viru
prophylaxi
nonatop
children
decreas
rel
risk
recurr
wheez
effect
infant
atop
famili
histori
suggest
rsv
predispos
recurr
wheez
atopyindepend
mechan
j
allergi
clin
immunol
asthma
import
chronic
diseas
childhood
prospect
epidemiolog
studi
respiratori
syncyti
viru
rsv
lower
respiratori
tract
infect
lrti
earli
life
demonstr
subsequ
rate
asthma
airway
hyperreact
greater
uninfect
control
year
later
unclear
whether
sever
rsv
lrti
occur
predispos
patient
asthma
whether
causal
subsequ
asthma
use
palivizumab
synagi
medimmun
inc
gaithersburg
md
market
outsid
usa
abbott
abbott
park
ill
human
mab
rsv
fusion
protein
prevent
sever
rsv
lrti
prospect
match
doubl
cohort
multicent
studi
prematur
infant
separ
effect
multivari
analysi
demonstr
prevent
sever
rsv
lrti
infanc
later
recurr
wheez
reduc
physiciandiagnos
recurr
wheez
compar
control
howev
larg
studi
conduct
wisconsin
childhood
origin
asthma
coast
studi
show
children
strong
famili
histori
atopi
rhinoviru
import
caus
develop
children
wheez
year
final
studi
australia
show
abbrevi
use
lrti
lower
respiratori
tract
infect
rr
rel
risk
rsv
respiratori
syncyti
viru
rhinoviru
rsv
interact
atopi
infanc
promot
later
asthma
suggest
requir
diseas
pathogenesi
studi
canada
show
exposur
parainfluenza
viru
rsv
first
year
life
associ
possibl
asthma
year
age
spanish
studi
show
human
metapneumoviru
rsv
infanc
associ
asthma
age
year
coast
studi
show
human
coronaviru
human
metapneumoviru
produc
asthma
age
year
thu
relationship
earli
rsv
lrti
allerg
sensit
develop
asthma
later
age
still
unresolv
controversi
prompt
us
examin
effect
famili
histori
atopi
prevent
later
recurr
wheez
prematur
infant
receiv
palivizumab
first
year
life
compar
control
prospect
multicent
match
doubl
cohort
studi
conduct
center
spain
germani
netherland
canada
poland
sweden
describ
earlier
briefli
children
month
age
receiv
palivizumab
previou
respiratori
season
hospit
rsv
match
basi
gestat
age
week
week
week
age
month
control
children
never
receiv
palivizumab
control
group
approxim
one
third
document
rsv
hospit
first
year
enrol
n
second
group
n
hospit
studi
particip
born
prematur
week
gestat
age
without
chronic
lung
diseas
never
receiv
vaccin
prevent
rsv
exclus
criteria
mechan
ventil
enrol
life
expect
month
known
immunodefici
written
inform
consent
obtain
subject
parent
legal
guardian
perform
studyrel
procedur
studi
conduct
accord
intern
confer
harmonis
technic
requir
registr
pharmaceut
human
use
ich
good
clinic
practic
guidelin
enrol
medic
sociodemograph
histori
taken
physic
examin
perform
serum
obtain
rsv
neutral
antibodi
ige
level
monthli
contact
parentscaregiv
schedul
month
enrol
visit
studi
site
conduct
interv
monthli
contact
conduct
telephon
patient
ill
medic
hospit
medic
event
past
month
record
monthli
followup
contact
interv
physician
record
also
review
intercurr
doctor
visit
emerg
visit
hospit
respiratori
symptom
episod
wheez
defin
consecut
day
wheez
preced
follow
nonwheez
healthi
period
least
week
physiciandiagnos
recurr
wheez
defin
episod
wheez
last
month
verifi
physician
physician
visit
emerg
depart
visit
hospit
report
includ
data
collect
month
followup
three
studi
group
defin
protocol
infant
receiv
palivizumab
prophylaxi
control
prophylax
palivizumab
histori
rsv
hospit
unprophylax
control
without
rsv
hospit
analys
compar
prophylax
group
combin
untreat
group
nonhospit
untreat
group
post
hoc
subgroup
infant
determin
basi
whether
follow
present
baselin
famili
histori
asthma
famili
histori
atopi
asthma
atop
dermat
allerg
rhiniti
food
allergi
famili
defin
anyon
immedi
famili
analys
perform
within
subgroup
sampl
size
infant
per
group
would
provid
approxim
power
test
detect
statist
signific
differ
physiciandiagnos
recurr
wheez
rate
true
rate
prophylax
group
untreat
control
studi
power
test
differ
within
subgroup
previous
specifi
demograph
baselin
characterist
analyz
quantit
variabl
use
anova
categor
variabl
use
fisher
exact
test
comparison
treat
untreat
group
incid
physiciandiagnos
recurr
wheez
perform
use
fisher
exact
test
rel
risk
rr
ci
rr
calcul
potenti
influenc
baselin
characterist
explor
multipl
logist
regress
covari
rsv
hospit
histori
sex
age
enrol
gestat
age
birth
birth
weight
multipl
birth
statu
baselin
rsvneutral
antibodi
titer
log
rsv
antibodi
level
day
care
attend
number
adult
sibl
home
number
sibl
day
care
presenc
woodburn
stove
home
famili
histori
asthma
atop
dermat
allerg
rhiniti
food
allergi
time
third
physiciandiagnos
wheez
episod
analyz
multivari
cox
proport
hazard
model
includ
covari
list
logist
regress
cox
proport
hazard
analysi
forward
stepwis
select
method
use
determin
factor
signific
level
factor
includ
final
model
factor
signific
level
final
model
display
comparison
treat
untreat
group
time
third
physiciandiagnos
wheez
episod
perform
use
logrank
test
kaplanmei
estim
comput
display
graphic
children
palivizumabtr
group
untreat
group
among
hospit
rsv
hospit
rsv
center
enrol
subject
subject
discontinu
day
cutoff
sixteen
palivizumabtr
group
versu
children
receiv
palivizumab
discontinu
day
differ
statist
signific
p
demograph
baselin
characterist
group
stratifi
absenc
presenc
famili
histori
atopi
food
allergi
present
tabl
ii
respect
children
famili
histori
atopi
food
allergi
children
famili
histori
atopi
food
allergi
enrol
studi
subject
famili
histori
atopi
food
allergi
untreat
group
significantli
children
multipl
birth
accordingli
sibl
palivizumabtr
group
tabl
famili
histori
atopi
food
allergi
children
day
care
untreat
group
compar
treat
group
subgroup
untreat
infant
greater
mean
gestat
age
birth
weight
palivizumabtr
infant
tabl
ii
expect
guidelin
palivizumab
use
favor
treatment
smaller
prematur
infant
combin
untreat
group
also
statist
significantli
lower
proport
infant
baselin
rsv
antibodi
less
compar
treat
group
within
subgroup
infant
famili
histori
atopi
food
allergi
demograph
factor
compar
treat
untreat
group
significantli
smaller
proport
palivizumabtr
children
physiciandiagnos
recurr
wheez
first
month
followup
compar
combin
untreat
group
subgroup
children
famili
histori
asthma
p
famili
histori
atopi
food
allergi
p
similar
differ
palivizumabtr
group
nonhospit
untreat
group
also
seen
howev
differ
within
subgroup
famili
histori
asthma
statist
signific
p
fig
rel
incid
rate
reduct
signific
subgroup
infant
famili
histori
allergi
atopyfood
allergi
fig
potenti
influenc
baselin
characterist
incid
respiratori
outcom
explor
multipl
logist
regress
tabl
iii
palivizumab
treatment
associ
signific
reduct
risk
physiciandiagnos
recurr
wheez
infant
without
famili
atopyallergi
histori
reduct
odd
event
famili
histori
asthma
histori
atopi
food
allergi
contrast
subgroup
famili
histori
atopi
food
allergi
palivizumab
treatment
signific
effect
occurr
physiciandiagnos
recurr
wheez
signific
factor
famili
histori
asthma
atopyfood
allergi
birth
weight
andor
gestat
age
greater
valu
reduc
risk
event
contrast
children
famili
histori
asthma
member
multipl
birth
sibl
day
care
significantli
increas
risk
physiciandiagnos
recurr
wheez
wherea
sibl
home
decreas
risk
examin
time
third
episod
physiciandiagnos
wheez
use
kaplanmei
methodolog
fig
palivizumabtr
group
demonstr
significantli
longer
time
third
episod
subgroup
infant
famili
histori
asthma
atopyfood
allergi
contrast
subgroup
infant
famili
histori
asthma
atopyfood
allergi
differ
time
third
episod
treat
untreat
group
statist
signific
potenti
influenc
baselin
characterist
time
third
episod
physiciandiagnos
wheez
explor
use
multivari
cox
proport
hazard
regress
model
palivizumab
treatment
remain
associ
significantli
longer
time
third
episod
subgroup
infant
famili
histori
asthma
famili
atopyfood
allergi
histori
tabl
iv
greater
gestat
age
also
associ
longer
time
third
episod
subgroup
contrast
palivizumab
appear
signific
effect
famili
histori
asthma
atopyfood
allergi
interestingli
subgroup
infant
famili
histori
atopi
food
allergi
famili
histori
asthma
signific
risk
factor
time
third
episod
physiciandiagnos
wheez
result
coast
studi
subsequ
studi
australia
appear
contrast
initi
find
administr
palivizumab
infanc
protect
prematur
subject
subsequ
recurr
wheez
first
year
life
prompt
us
examin
potenti
differenti
effect
rsv
prevent
without
atop
diathesi
find
signific
protect
children
famili
histori
asthma
atopi
suggest
differ
may
explain
atop
diathesi
thu
wherea
studi
conduct
preterm
children
wherea
recruit
almost
equival
number
children
atop
background
nonatop
background
coast
studi
consist
almost
entir
infant
atop
background
examin
effect
rhinoviru
infect
earli
infanc
children
atop
group
could
comment
relationship
earli
rhinoviru
infect
later
subsequ
asthma
howev
appar
lack
effect
prevent
rsv
atop
subject
fit
well
appar
lack
independ
effect
earli
life
rsv
seen
coast
studi
rel
low
number
children
studi
famili
histori
asthma
may
part
explain
nonsignific
reduct
group
group
children
atop
famili
histori
howev
almost
number
children
atop
histori
consist
find
subgroup
basi
absenc
famili
atopyallergi
histori
increas
protect
least
point
estim
success
atop
background
remov
famili
histori
asthma
famili
histori
atopi
food
allergi
despit
lower
number
children
famili
histori
atopi
food
allergi
suggest
observ
real
subject
trial
recruit
mean
age
month
rang
month
possibl
children
alreadi
recurr
wheez
episod
physiciandiagnos
recurr
wheez
age
examin
subgroup
children
famili
histori
atopi
food
allergi
multipl
logist
regress
palivizumab
treatment
reduc
risk
physiciandiagnos
recurr
wheez
contrast
palivizumab
signific
effect
histori
children
recurr
wheez
group
may
recurr
wheez
sever
reason
minor
would
asthma
start
earli
life
would
recurr
wheez
rsv
occur
enrol
would
definit
episod
recurr
wheez
case
enrol
subject
year
age
complet
studi
may
earli
hereditari
allerg
factor
exert
effect
wheez
howev
allerg
factor
may
exert
effect
influenc
palivizumab
less
appar
subject
children
within
group
protect
thu
probabl
atop
diathesi
would
probabl
go
develop
asthma
later
life
precis
within
group
maximum
protect
seen
none
patient
palivizumab
group
control
group
hospit
rsv
possibl
result
reflect
sever
previou
rsv
diseas
control
group
henc
compar
outcom
treat
control
group
hospit
rsv
still
signific
differ
palivizumabtr
nonhospit
untreat
group
subgroup
famili
histori
atopi
food
allergi
logist
regress
analysi
show
major
factor
associ
reduct
physiciandiagnos
recurr
wheez
treatment
palivizumab
without
atop
diathesi
famili
histori
atopi
asthma
may
risk
factor
sever
lrti
earli
life
rsv
hospit
patient
famili
histori
asthma
effect
palivizumab
appear
margin
suggest
atop
asthmat
background
sever
enough
predispos
factor
develop
later
occur
wheez
perhap
rsv
infect
increas
risk
much
thesi
support
part
observ
cox
regress
model
clearli
show
atop
diathesi
food
allergi
famili
histori
asthma
still
strongest
predictor
recurr
wheez
later
prevent
palivizumab
rsv
appear
signific
effect
popul
studi
show
protect
effect
overal
popul
background
atopi
food
allergi
consist
effect
appear
strong
indic
rsv
may
lead
recurr
wheez
popul
whether
effect
persist
later
childhood
adult
life
question
remain
answer
studi
australia
seem
suggest
earlylif
respiratori
infect
either
rsv
rhinoviru
conjunct
atop
sensit
may
contribut
risk
subsequ
develop
persist
asthma
time
studi
tucson
predict
children
persist
wheez
age
year
conjunct
famili
histori
asthma
predict
onset
later
asthma
adulthood
studi
clearli
answer
question
genesi
later
childhood
asthma
adultonset
asthma
observ
lend
intrigu
possibl
perhap
prevent
rsv
infect
earli
life
prevent
sensit
potenti
develop
later
asthma
hypothesi
suggest
data
mous
model
infect
support
studi
rsv
prophylaxi
human
be
mous
model
rsv
infect
shown
respiratori
infect
young
mice
sensit
mice
aeroallergen
expos
infect
howev
recent
studi
suggest
remodel
rsv
mous
model
occur
without
sensit
previou
studi
use
rsv
immunoglobulin
suggest
combin
immunosuppress
effect
high
dose
monthli
prophylact
immunoglobulin
antirsv
activ
rsv
immunoglobulin
given
children
chronic
lung
diseas
prematur
abrog
develop
abnorm
lung
function
year
age
futur
studi
random
control
trial
rsv
infect
use
mab
children
without
atop
background
plan
address
role
rsv
develop
subsequ
asthma
prematur
infant
prevent
rsv
use
palivizumab
children
without
atop
background
appear
decreas
rel
risk
recurr
wheez
year
age
effect
seen
atop
background
clinic
implic
rsv
prophylaxi
palivizumab
significantli
reduc
rel
risk
subsequ
recurr
wheez
nonatop
prematur
infant
